FAM
KRYS icon

Fred Alger Management’s Krystal Biotech KRYS Stock Holding History

Fred Alger Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,728
Closed -$672K – 462
2025
Q1 		$672K Buy
+3,728
New +$627K ﹤0.01% 345
2024
Q1 		– Sell
-160,335
Closed -$19.9M – 473
2023
Q4 		$19.9M Sell
160,335
-7,150
-4% -$793K 0.11% 140
2023
Q3 		$19.4M Buy
167,485
+163,928
+4,609% +$20M 0.11% 146
2023
Q2 		$418K Buy
+3,557
New +$363K ﹤0.01% 405

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fred Alger Management's KRYS Position: Q2 2025 in Review

Fred Alger Management sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 3,728 shares — an estimated $672K sold.

Fred Alger Management first reported a position in KRYS in Q2 2023 and held it in 4 quarters. The position peaked at $19.9M in Q4 2023. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Fred Alger Management reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • Fred Alger Management sold 3,728 Krystal Biotech shares in Q2 2025, an estimated $672K.
  • Fred Alger Management first reported a position in Krystal Biotech in Q2 2023 and held it in 4 quarters.
  • Fred Alger Management's Krystal Biotech position peaked at $19.9M in Q4 2023.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Fred Alger Management's 13F filing for Q2 2025, filed 14 Aug 2025.